Belkin Vision announced that it has received €17.5M of blended financing in grants and equity from the European Innovation Council Accelerator (EIC). Belkin Vision's glaucoma laser is currently in the final stages of clinical trials across the UK and Europe, and if approved, would be the first and only contactless laser treatment for glaucoma, according to a company news release.

To date, Belkin Vision has raised $19M through investors and is also a past recipient of the EU Horizon 2020, which was instrumental in aiding the company to achieve many milestones including the completion of its pivotal multicenter clinical trial, for which results are expected in 2022. The additional funds will be used to begin commercialization and to scale up the company up at a higher rate, initially in Europe and then globally to bring accessible glaucoma care to all. The company anticipates a controlled roll-out in Europe in late 2022.

"We couldn't be happier to be selected to receive EIC funding. This validation from the EU will help us to continue to drive our technology forward, allowing us to bring to market a treatment for glaucoma which will significantly impact population health and the prevention of blindness worldwide. We are grateful for the EIC's support and look forward to a successful partnership," Daria Lemann Blumenthal, CEO of Belkin Vision, said in a company news release.